Immunotherapy for Stage III NSCLC: Durvalumab and Beyond

Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non–small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown to be efficacious in the landmark PACIFIC trial with 1 year of main...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzpatrick, Orla, Naidoo, Jarushka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572112/
https://www.ncbi.nlm.nih.gov/pubmed/34754256
http://dx.doi.org/10.2147/LCTT.S305466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572112/
https://www.ncbi.nlm.nih.gov/pubmed/34754256
http://dx.doi.org/10.2147/LCTT.S305466

Ejemplares similares